In an in vivo model of Alzheimer’s disease (i.e., an AβPP/PS1 transgenic mouse model), treatment with JWH133 (200 nM) has been shown to lead to cognitive improvement, the results of which were associated with decreased microglial reactivity and a reduced expression of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and IFNγ [89]. The gene discussed is IFNG; the disease is Alzheimer disease.